Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas

NCT03021057 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

33

Enrollment

OTHER

Sponsor class

Conditions

T-Cell Lymphoma
NK-Cell Lymphoma

Interventions

DRUG: pembrolizumab

Sponsor

The University of Hong Kong

Collaborators

[object Object]